Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial
Gespeichert in:
| Titel: | Salvage therapy with gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for B-cell non-Hodgkin’s lymphoma: a consortium for improving survival of lymphoma (CISL) trial |
|---|---|
| Autoren: | Byeong Bae Park, Dae Ho Lee, Young Yiul Lee, Sukjoong Oh, Cheolwon Suh, Won Seog Kim, Hyeon Seok Eom, Jin Seok Kim |
| Weitere Verfasser: | Byeong-Bae Park, Won Seog Kim, Hyeon Seok Eom, Jin Seok Kim, Young Yiul Lee, Suk Joong Oh, Dae Ho Lee, Cheolwon Suh, Kim, Jin Seok |
| Quelle: | Investigational New Drugs. 29:154-160 |
| Verlagsinformationen: | Springer Science and Business Media LLC, 2009. |
| Publikationsjahr: | 2009 |
| Schlagwörter: | Dexamethasone/administration & dosage, Adult, Male, Deoxycytidine/analogs & derivatives, Lymphoma, Organoplatinum Compounds, Salvage therapy, Antineoplastic Agents, Ifosfamide/therapeutic use, Salvage Therapy, Deoxycytidine, Dexamethasone, Disease-Free Survival, Dexamethasone/therapeutic use, Non-Hodgkin/pathology, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Humans, Organoplatinum Compounds/adverse effects, Ifosfamide, Organoplatinum Compounds/administration & dosage, Deoxycytidine/administration & dosage, Aged, B-Lymphocytes, Deoxycytidine/adverse effects, Dexamethasone/adverse effects, Lymphoma, Non-Hodgkin, Antineoplastic Agents/therapeutic use, Antineoplastic Agents/adverse effects, Non-Hodgkin/drug therapy, Ifosfamide/adverse effects, Middle Aged, Organoplatinum Compounds/therapeutic use, Ifosfamide/administration & dosage, Gemcitabine, Antineoplastic Agents/administration & dosage, 3. Good health, B-Lymphocytes/pathology, Oxaliplatin, Treatment Outcome, Non-Hodgkin's lymphoma, Female, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Deoxycytidine/therapeutic use |
| Beschreibung: | We investigated response rates to and toxicities of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).Patients with recurrent or refractory diffuse large B-cell lymphoma or mantle cell lymphoma (DLBCL) were eligible for enrollment in this study. Treatment consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on Days 1 and 8, ifosfamide 2,000 mg/m(2) i.v. on Day 1, dexamethasone 40 mg orally on Days 1-4, and oxaliplatin 130 mg/m(2) i.v. on Day 2, every 21 days. The primary goal of treatment was to establish a response rate after three cycles. Afterwards, patients could proceed to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) or receive up to six treatment cycles.Twenty-seven eligible patients were evaluated for toxicity and response. The median age of the patients was 54 years (range, 18-75 years), and most had DLBCL. After three cycles, there were four CR (15%) and 10 PR (37%) for an overall response rate (RR) of 52%. Among a total of 88 GIDOX cycles, grade 3 and 4 neutropenia occurred in 33% and 16% of the cycles, respectively. Likewise, grade 3 and 4 thrombocytopenia occurred in 14% and 16% of the cycles, respectively. Two patients (2%) experienced febrile neutropenia, while seven patients (26%) proceeded to HDC-ASCT.GIDOX is an active salvage regimen for aggressive B-cell NHL and can be tolerated by patients with acceptable toxicity. |
| Publikationsart: | Article |
| Sprache: | English |
| ISSN: | 1573-0646 0167-6997 |
| DOI: | 10.1007/s10637-009-9320-y |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/19756371 https://link.springer.com/content/pdf/10.1007%2Fs10637-009-9320-y.pdf https://link.springer.com/article/10.1007/s10637-009-9320-y/fulltext.html https://mdanderson.elsevierpure.com/en/publications/salvage-therapy-with-gemcitabine-ifosfamide-dexamethasone-and-oxa http://www.ncbi.nlm.nih.gov/pubmed/19756371 https://pubmed.ncbi.nlm.nih.gov/19756371/ https://link.springer.com/article/10.1007/s10637-009-9320-y |
| Rights: | Springer Nature TDM CC BY NC ND |
| Dokumentencode: | edsair.doi.dedup.....1e088891f35fbb4d0540e38dc0ccb370 |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | We investigated response rates to and toxicities of gemcitabine, ifosfamide, dexamethasone, and oxaliplatin (GIDOX) for the treatment of relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).Patients with recurrent or refractory diffuse large B-cell lymphoma or mantle cell lymphoma (DLBCL) were eligible for enrollment in this study. Treatment consisted of gemcitabine 1,000 mg/m(2) intravenously (i.v.) on Days 1 and 8, ifosfamide 2,000 mg/m(2) i.v. on Day 1, dexamethasone 40 mg orally on Days 1-4, and oxaliplatin 130 mg/m(2) i.v. on Day 2, every 21 days. The primary goal of treatment was to establish a response rate after three cycles. Afterwards, patients could proceed to high-dose chemotherapy followed by autologous stem cell transplantation (HDC-ASCT) or receive up to six treatment cycles.Twenty-seven eligible patients were evaluated for toxicity and response. The median age of the patients was 54 years (range, 18-75 years), and most had DLBCL. After three cycles, there were four CR (15%) and 10 PR (37%) for an overall response rate (RR) of 52%. Among a total of 88 GIDOX cycles, grade 3 and 4 neutropenia occurred in 33% and 16% of the cycles, respectively. Likewise, grade 3 and 4 thrombocytopenia occurred in 14% and 16% of the cycles, respectively. Two patients (2%) experienced febrile neutropenia, while seven patients (26%) proceeded to HDC-ASCT.GIDOX is an active salvage regimen for aggressive B-cell NHL and can be tolerated by patients with acceptable toxicity. |
|---|---|
| ISSN: | 15730646 01676997 |
| DOI: | 10.1007/s10637-009-9320-y |